비욘드바이오

BEY1107 (Avotaciclib)

Pancreatic cancer, colorectal cancer, and glioblastoma treatment

An anti-cancer agent that selectively acts on CDK1 among the cyclin-dependent kinases (CDKs) that regulate the cell cycle

BEY1107 induces apoptosis by arresting the cell cycle at the G2/M phase, thereby promoting programmed cell death in cancer cells. It also inhibits the AKT signaling pathway, leading to decreased expression of factors involved in cancer cell proliferation, survival, chemoresistance, and metastasis. Furthermore, BEY1107 suppresses Sox2, thereby inhibiting the self-renewal of cancer stem cells and demonstrating effectiveness as a monotherapy.

In particular, when combined with cytotoxic anti-cancer drugs such as Gemcitabine, Capecitabine, and Temozolomide, BEY1107 has shown enhanced therapeutic effects and is expected to overcome drug resistance and recurrence induced by cytotoxic anti-cancer drugs.

Currently, BEY1107 is in phase I clinical trials in patients with pancreatic cancer, colorectal cancer, and glioblastoma, with the goal of entering Phase II trials in 2026.